Opendata, web and dolomites

CHAMPION SIGNED

Cartilage Healing Approach Merging Polymer InnOvation with Nature

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CHAMPION project word cloud

Explore the words cloud of the CHAMPION project. It provides you a very rough idea of what is the project "CHAMPION" about.

focal    total    human    symptomatic    outside    limited    mark    form    gained    centres    polyethylene    degradation    clinical    acellular    rate    requiring    light    limiting    excellence    stem    pursuit    implants    cured    mode    outcome    designed    optimal    quick    situ    differentiate    re    biologicals    replacement    osteoarthritis    longterm    chondrocytes    barrier    defects    migration    harnesses    ultraviolet    articular    hyaline    body    2017    million    successful    unlike    synchronized    bone    gradually    inwards    cartilage    prochondrogenic    action    implant    risks    cellular    commercialization    surgery    treatments    cell    ce    poor    off    resorbs    injury    trials    cells    preventing    ready    liquid    multiple    channels    replaced    time    fibrinogen    right    promise    annually    painful    microenvironment    knee    marrow    stimulation    elusive    procedure    entrance    regulatory    failed    treatment    shelf    therapeutic    complexity    benefit    completing    glycol    gelrinc    joint    defect    resorbable    market    alternative    denatured    implantation    microfracture    shape    frequent    afflicts    interventions    undesired    optimizing    patients    conforming    arthroscopic    injuries    realized   

Project "CHAMPION" data sheet

The following table provides information about the project.

Coordinator
REGENTIS BIOMATERIALS LTD 

Organization address
address: HA ILAN STREET 2 NORTHERN INDUSTRIAL ZONE
city: OR AKIVA
postcode: 30600
website: www.regentis.co.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙121˙700 €
 EC max contribution 2˙185˙190 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGENTIS BIOMATERIALS LTD IL (OR AKIVA) coordinator 2˙185˙190.00

Map

 Project objective

Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process. GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials,improving the procedure towards arthroscopic implantation; and creating commercialization channels including centres of excellence in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHAMPION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHAMPION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

EDITUS (2019)

Helping our customers to design smart and safe tomorrows’ communication systems

Read More  

Presque (2019)

Smart Nursing Bra

Read More